Learn what the HHS 340B Drug Pricing Program is and what 340B hospitals are. The program allows 340B hospitals to stretch limited federal resources to reduce the price of outpatient pharmaceuticals ...

Under the 340B program, eligible hospitals buy drugs at a discounted price in order to offset the cost of treating low income ...

The American Hospital Association, a Maine hospital group and four nonprofit systems are seeking a temporary restraining ...

At a recent Senate hearing, which refocused attention on the broken 340B Drug Pricing Program, lawmakers were reminded of how ...

___ Karen L. van Caulil, Ph.D., is the Executive Director of Floridians for Accountability in Health Care. Doug Wheeler is the Director of the George Gibbs Center for Economic Prosperity at The James ...

The 340B Drug Pricing Program continues to provide critical support for covered entities, although the program is subject to ongoing scrutiny and congressional, judicial, and industry pressures.

The Patient Protection and Affordable Care Act is expected to bring significant change to the healthcare industry, including the expansion of the Public Health Service Act Section 340B Program.

Weaknesses in the oversight of the 340 drug-pricing program may allow some hospitals to get discounts they are ineligible for, a newly released report from the Government Accountability Office found.

When the 340B drug pricing program was established in 1992, Congress intended for the program to help low-income and uninsured patients with their prescription drugs. The pharmaceutical companies ...

I’m fortunate to have access to lifesaving treatments that give me more time with my loved ones, and every patient deserves the same chance.

In U.S. healthcare, few policies are as poorly designed as the 340B drug discount program. But despite solid evidence that the program is poorly managed, the government has once again denied being ...

The 340B Drug Pricing Program (“340B Program”) space continues to be a hive of activity. While 340B stakeholders continue to litigate ongoing manufacturer contract pharmacy restrictions, states ...